Literature DB >> 19414578

Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 beta-lactamase.

Yohei Doi1, David L Paterson, Jennifer M Adams-Haduch, Hanna E Sidjabat, Alexandra O'Keefe, Andrea Endimiani, Robert A Bonomo.   

Abstract

Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the bla(CMY) genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19414578      PMCID： PMC2704647          DOI： 10.1128/AAC.00133-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

Review 1.  Plasmid-determined AmpC-type beta-lactamases.

Authors:  Alain Philippon; Guillaume Arlet; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

Review 2.  Plasmid-borne AmpC beta-lactamases.

Authors:  Jan Walther-Rasmussen; Niels Høiby
Journal:  Can J Microbiol       Date:  2002-06       Impact factor: 2.419

3.  Structural basis for the extended substrate spectrum of CMY-10, a plasmid-encoded class C beta-lactamase.

Authors:  Jae Young Kim; Ha Il Jung; Young Jun An; Jung Hun Lee; So Jung Kim; Seok Hoon Jeong; Kye Joon Lee; Pann-Ghill Suh; Heung-Soo Lee; Sang Hee Lee; Sun-Shin Cha
Journal:  Mol Microbiol       Date:  2006-05       Impact factor: 3.501

4.  CMY-16, a novel acquired AmpC-type beta-lactamase of the CMY/LAT lineage in multifocal monophyletic isolates of Proteus mirabilis from northern Italy.

Authors:  Marco M D'Andrea; Elisabetta Nucleo; Francesco Luzzaro; Tommaso Giani; Roberta Migliavacca; Francesca Vailati; Vesselina Kroumova; Laura Pagani; Gian Maria Rossolini
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Horizontal transfer of blaCMY-bearing plasmids among clinical Escherichia coli and Klebsiella pneumoniae isolates and emergence of cefepime-hydrolyzing CMY-19.

Authors:  Jun-ichi Wachino; Hiroshi Kurokawa; Satowa Suzuki; Kunikazu Yamane; Naohiro Shibata; Kouji Kimura; Yasuyoshi Ike; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

6.  Extension of resistance to cefepime and cefpirome associated to a six amino acid deletion in the H-10 helix of the cephalosporinase of an Enterobacter cloacae clinical isolate.

Authors:  G Barnaud; R Labia; L Raskine; M J Sanson-Le Pors; A Philippon; G Arlet
Journal:  FEMS Microbiol Lett       Date:  2001-02-20       Impact factor: 2.742

7.  Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.

Authors:  Fred C Tenover; Shannon L Emery; Carol A Spiegel; Patricia A Bradford; Samantha Eells; Andrea Endimiani; Robert A Bonomo; John E McGowan
Journal:  J Clin Microbiol       Date:  2008-11-26       Impact factor: 5.948

8.  Inhibitor-sensitive AmpC beta-lactamase variant produced by an Escherichia coli clinical isolate resistant to oxyiminocephalosporins and cephamycins.

Authors:  Yohei Doi; Jun-ichi Wachino; Masaji Ishiguro; Hiroshi Kurokawa; Kunikazu Yamane; Naohiro Shibata; Keigo Shibayama; Keiko Yokoyama; Haru Kato; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

9.  Selection during cefepime treatment of a new cephalosporinase variant with extended-spectrum resistance to cefepime in an Enterobacter aerogenes clinical isolate.

Authors:  G Barnaud; Y Benzerara; J Gravisse; L Raskine; M J Sanson-Le Pors; R Labia; G Arlet
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

10.  Resistance to cefepime and cefpirome due to a 4-amino-acid deletion in the chromosome-encoded AmpC beta-lactamase of a Serratia marcescens clinical isolate.

Authors:  Hedi Mammeri; Laurent Poirel; Pascal Bemer; Henri Drugeon; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
View more
  14 in total

Review 1.  Updated functional classification of beta-lactamases.

Authors:  Karen Bush; George A Jacoby
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

2.  N152G, -S, and -T substitutions in CMY-2 β-lactamase increase catalytic efficiency for cefoxitin and inactivation rates for tazobactam.

Authors:  Marion J Skalweit; Mei Li; Benjamin C Conklin; Magdalena A Taracila; Rebecca A Hutton
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

3.  Molecular epidemiology of KPC-producing Escherichia coli: occurrence of ST131-fimH30 subclone harboring pKpQIL-like IncFIIk plasmid.

Authors:  Jessica A O'Hara; Fupin Hu; Chulsoo Ahn; Jeremy Nelson; Jesabel I Rivera; Anthony W Pasculle; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

4.  In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.

Authors:  João Pires; Magdalena Taracila; Christopher R Bethel; Yohei Doi; Sara Kasraian; Regula Tinguely; Parham Sendi; Robert A Bonomo; Andrea Endimiani
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  Increased Hydrolysis of Oximino-β-Lactams by CMY-107, a Tyr199Cys Mutant Form of CMY-2 Produced by Escherichia coli.

Authors:  S D Kotsakis; V Miriagou; E E Vetouli; E Bozavoutoglou; E Lebessi; E Tzelepi; L S Tzouvelekis
Journal:  Antimicrob Agents Chemother       Date:  2015-10-05       Impact factor: 5.191

6.  Dissemination of clinical isolates of Klebsiella oxytoca harboring CMY-31, VIM-1, and a New OXY-2-type variant in the community.

Authors:  Athanassios Tsakris; Aggeliki Poulou; Fani Markou; Vassiliki Pitiriga; Evangelia-Theophano Piperaki; Ioulia Kristo; Spyros Pournaras
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

7.  Hydrolysis spectrum extension of CMY-2-like β-lactamases resulting from structural alteration in the Y-X-N loop.

Authors:  Sandrine Dahyot; Hedi Mammeri
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

8.  Features of infections due to Klebsiella pneumoniae carbapenemase-producing Escherichia coli: emergence of sequence type 131.

Authors:  Young Ah Kim; Zubair A Qureshi; Jennifer M Adams-Haduch; Yoon Soo Park; Kathleen A Shutt; Yohei Doi
Journal:  Clin Infect Dis       Date:  2012-04-04       Impact factor: 9.079

Review 9.  Class C β-Lactamases: Molecular Characteristics.

Authors:  Alain Philippon; Guillaume Arlet; Roger Labia; Bogdan I Iorga
Journal:  Clin Microbiol Rev       Date:  2022-04-18       Impact factor: 50.129

10.  Predatory bacteria: a potential ally against multidrug-resistant Gram-negative pathogens.

Authors:  Daniel E Kadouri; Kevin To; Robert M Q Shanks; Yohei Doi
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.